Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials

OBJECTIVE: Disability assessment for dementia (DAD) measurements from two phase-3 studies of bapineuzumab in APOE ε4 noncarrier and carrier Alzheimer's disease (AD) patients were integrated to develop a disease progression model. METHODS: We evaluated longitudinal changes in DAD scores, baselin...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Steven X., Samtani, Mahesh N., Russu, Alberto, Adedokun, Omoniyi J., Lu, Ming, Ito, Kaori, Corrigan, Brian, Raje, Sangeeta, Brashear, H. Robert, Styren, Scot, Hu, Chuanpu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975025/
https://www.ncbi.nlm.nih.gov/pubmed/29854934
http://dx.doi.org/10.1016/j.trci.2015.06.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975025/
https://www.ncbi.nlm.nih.gov/pubmed/29854934
http://dx.doi.org/10.1016/j.trci.2015.06.005

Ejemplares similares